Literature DB >> 25146662

Pharmacological appetite stimulation: rational choices in the inappetent cat.

Wendy Agnew1, Rachel Korman2.   

Abstract

PRACTICAL RELEVANCE: Inappetence is a commonly encountered problem in feline medicine. Primary goals in managing the inappetent or anorectic cat are to diagnose and treat the underlying disease and reinstate adequate nutrition. RATIONALE: As cats are intolerant of prolonged periods of inadequate nutritional intake, especially given their propensity to develop hepatic lipidosis, their increased requirements for amino acids, and inability to slow their rate of gluconeogenesis, symptomatic therapy and nutritional support is often required during diagnostic investigations. CLINICAL CHALLENGES: Most cats presenting with reduced food intake will be suffering from an underlying systemic disease, and so the mechanism of action, pharmacokinetics and contraindications of appetite-stimulating medications will need to be considered in each case to ensure rational use of these agents. Pharmacological appetite stimulation should never replace monitoring and ensuring adequate caloric intake, and may not be appropriate in some cases, such as critically ill or severely malnourished patients. EVIDENCE BASE: While there are no medications approved specifically for the treatment of anorexia in cats, some drugs have proven efficacious in the clinical field. Although several agents have been used historically for appetite stimulation, due to potential side effects and/or lack of efficacy or predictability only cyproheptadine and mirtazapine can currently be recommended for use. © ISFM and AAFP 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25146662     DOI: 10.1177/1098612X14545273

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  3 in total

Review 1.  Capromorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs.

Authors:  Linda Rhodes; Bill Zollers; Jessica A Wofford; Ernst Heinen
Journal:  Vet Med Sci       Date:  2017-11-06

2.  A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss.

Authors:  Melinda Poole; Jessica M Quimby; Tianhua Hu; Daizie Labelle; William Buhles
Journal:  J Vet Pharmacol Ther       Date:  2018-12-02       Impact factor: 1.786

3.  In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease.

Authors:  Rikki L Fitzpatrick; Jessica M Quimby; Kellyi K Benson; Dominique Ramirez; Liberty G Sieberg; Luke A Wittenburg; Daniel L Gustafson
Journal:  J Vet Intern Med       Date:  2018-10-11       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.